Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib

被引：31

作者：

Kim, Gene H. ^{[1
,2
]}

Levy, Alan ^{[3
]}

Compoginis, Goli ^{[1
,3
]}

机构：

[1] Univ So Calif, Dept Dermatol, Los Angeles, CA USA

[2] Univ So Calif, Dept Pathol, Los Angeles, CA 90089 USA

[3] Levy Dermatol, Memphis, TN USA

来源：

JOURNAL OF CUTANEOUS PATHOLOGY | 2013年 / 40卷 / 07期

关键词：

drug reaction; melanoma; panniculitis; vemurafenib; BRAF; GENETICS;

D O I：

10.1111/cup.12149

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Vemurafenib is an inhibitor of BRAF and is used to treat patients with metastatic melanoma who carry a V600E BRAF mutation. Recently, four patients have been described in the literature who developed a neutrophilic panniculitis following treatment with a BRAF inhibitor. We present an additional case and review the clinical findings of the cases reported to date.

引用

页码：667 / 669

页数：3

共 50 条

[31] Vemurafenib (PLX4032): An Orally Available Inhibitor of Mutated BRAF for the Treatment of Metastatic Melanoma
Heakal, Yasser
Kester, Mark
Savage, Scott
ANNALS OF PHARMACOTHERAPY, 2011, 45 (11) : 1399 - 1405
[32] Panniculitis With Necrotizing Granulomata in a Patient on BRAF Inhibitor (Dabrafenib) Therapy for Metastatic Melanoma
Ramani, Nisha S.
Curry, Jonathan L.
Kapil, Jyoti
Rapini, Ronald P.
Tetzlaff, Michael T.
Prieto, Victor G.
Torres-Cabala, Carlos A.
AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2015, 37 (08) : e96 - e99
[33] Erythema Nodosum-Like Panniculitis in Patients With Melanoma Treated With Vemurafenib
Sinha, Rishika
Edmonds, Kim
Newton-Bishop, Julia
Gore, Martin
Larkin, James
Fearfield, Louise
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (19) : E320 - E321
[34] Vemurafenib-induced histiocytoid neutrophilic panniculitis simulating myeloid leukaemia cutis A novel variant of BRAF inhibitor associated panniculitis with histiocytoid infiltrate of immature neutrophils
Anika Richarz, Nina
Puig, Luis
Perez, Noelia
Cuadra-Urteaga, Jose
Elez, Elena
Teresa Fernandez-Figueras, Maria
CANCER BIOLOGY & THERAPY, 2019, 20 (03) : 237 - 239
[35] Transcriptomic Alterations Induced By Vemurafenib after Treatment of Melanoma: A Comprehensive Bioinformatics Analysis
Xie, J.
Cao, Y.
Zhu, Z.
Ruan, S.
Wang, M.
Shi, J.
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 83 : 195 - 207
[36] Vemurafenib beyond progression in a patient with metastatic melanoma: a case report
Grimaldi, Antonio M.
Simeone, Ester
Palla, Marco
Festino, Lucia
Caraco, Corrado
Mozzillo, Nicola
Petrillo, Antonella
Muto, Paolo
Ascierto, Paolo A.
ANTI-CANCER DRUGS, 2015, 26 (04) : 464 - 468
[37] Drug safety evaluation of vemurafenib in the treatment of melanoma
Tsai, Kenneth Y.
Nowroozi, Sasan
Kim, Kevin B.
EXPERT OPINION ON DRUG SAFETY, 2013, 12 (05) : 767 - 775
[38] Vemurafenib and ipilimumab: New agents for metastatic melanoma
Banaszynski, Megan
Kolesar, Jill M.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (14) : 1205 - 1210
[39] Photodynamic Therapy for Multiple Eruptive Keratoacanthomas Associated With Vemurafenib Treatment for Metastatic Melanoma
Alloo, Allireza
Garibyan, Lilit
LeBoeuf, Nicole
Lin, George
Werchniak, Andrew
Hodi, F. Stephen, Jr.
Flaherty, Keith T.
Lawrence, Donald P.
Lin, Jennifer Y.
ARCHIVES OF DERMATOLOGY, 2012, 148 (03) : 363 - 366
[40] Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study
Kaehler, Katharina C.
Gutzmer, Ralf
Meier, Friedegrund
Zimmer, Lisa
Heppt, Markus
Gesierich, Anja
Thoms, Kai-Martin
Utikal, Jochen
Hassel, Jessica C.
Loquai, Carmen
Pfoehler, Claudia
Heinzerling, Lucie
Kaatz, Martin
Goeppner, Daniela
Pflugfelder, Annette
Bohne, Ann-Sophie
Satzger, Imke
Reinhardt, Lydia
Placke, Jan-Malte
Schadendorf, Dirk
Ugurel, Selma
FRONTIERS IN ONCOLOGY, 2021, 11

← 1 2 3 4 5 →